ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3383-3395

  Kabbout, Mohamed ^a   Garcia, Melinda M ^a   Fujimoto, Junya ^a   Liu, Diane D ^a   Woods, Denise ^a   Chow, Chi Wan ^a   Mendoza, Gabriela ^a   Momin, Amin A ^a   James, Brian P ^a   Solis, Luisa ^a   Behrens, Carmen ^a   Lee, J Jack ^a   Wistuba, Ignacio I ^a   Kadara, Humam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTOME;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; ONCOGENE MET; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; RNA INTERFERENCE; CELL MOTION; CELL PROLIFERATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; RECURRENT DISEASE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS C-MET; RECURRENCE; SIGNAL TRANSDUCTION;

EID: 84879857687     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0341     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
3. Hsu T, Trojanowska M, Watson DK. Ets proteins in biological control and cancer. J Cell Biochem 2004;91:896-903.
4. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005;41:2462-78. (Pubitemid 41540623)
5. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001;2:827-37. (Pubitemid 33674083)
6. Yamamoto H, Flannery ML, Kupriyanov S, Pearce J, McKercher SR, Henkel GW,et al. Defective trophoblast function in mice with a targeted mutation of Ets2. Genes Dev 1998;12:1315-26. (Pubitemid 28213407)
7. Wei G, Srinivasan R, Cantemir-Stone CZ, Sharma SM, Santhanam R, Weinstein M, et al. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. Blood 2009;114:1123-30.
8. Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, Stacey KJ, et al. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 1996;16:538-47. (Pubitemid 26029092)
9. Xu D, Dwyer J, Li H, Duan W, Liu JP. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 2008;283:23567-80.
10. de Nigris F, Mega T, Berger N, Barone MV, Santoro M, Viglietto G, et al. Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. Cancer Res 2001;61:2267-75. (Pubitemid 32692058)
11. Liao YL, Hu LY, Tsai KW, Wu CW, Chan WC, Li SC, et al. Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells. Carcinogenesis 2012;33:760-9.
12. Munera J, Cecena G, Jedlicka P, Wankell M, Oshima RG. Ets2 regulates colonic stem cells and sensitivity to tumorigenesis. Stem Cells 2011;29:430-9.
13. Neznanov N, Man AK, Yamamoto H, Hauser CA, Cardiff RD, Oshima RG. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res 1999;59:4242-6. (Pubitemid 29418736)
14. Sementchenko VI, Schweinfest CW, Papas TS, Watson DK. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 1998;17:2883-8. (Pubitemid 29010058)
15. Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH. Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome. Nature 2008;451:73-5.
16. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 2011;17:2434-43.
17. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007;3:11-7. (Pubitemid 47075796)
18. Arriola E, Canadas I, Arumi-Uria M, Domine M, Lopez-Vilarino JA, Arpi O, et al. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer 2011;105:814-23.
19. Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012;7:331-9.
20. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-75. (Pubitemid 32708634)
21. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008;3:e1651.
22. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415-28. (Pubitemid 46809165)
23. Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, et al. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res 2010;70:1323-33.
24. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. (Pubitemid 37493640)
25. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4. (Pubitemid 21926175)
26. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55. (Pubitemid 37413476)
27. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends MolMed2010;16:37-45.
28. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011;30:3625-35.
29. Radtke S, Milanovic M, Rosse C, de Rycker M, Lachmann S, Hibbert A, et al. ERK2 but not ERK1 mediates HGF-induced motility in non small cell lung carcinoma cell lines. J Cell Sci 2013 Apr 2. [Epub ahead of print].
30. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010;2:26ra5.
31. Yamamoto Y, Nishimura N, Morimoto S, Kitamura H, Manabe S, Kanayama HO, et al. Distinct roles of Rab3B and Rab13 in the polarized transport of apical, basolateral, and tight junctional membrane proteins to the plasma membrane. Biochem Biophys Res Commun 2003;308:270-5. (Pubitemid 36937175)
32. Song L, Webb NE, Song Y, Tuan RS. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. Stem Cells 2006;24:1707-18. (Pubitemid 44474184)
33. Smith SL, Bowers NL, Betticher DC, Gautschi O, Ratschiller D, Hoban PR, et al. Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005;93:719-29. (Pubitemid 41486464)
34. Kwon YJ, Lee SJ, Koh JS, Kim SH, Lee HW, Kang MC, et al. Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J Thorac Oncol 2012;7:20-33.
35. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003;63:4626-31. (Pubitemid 36951040)
36. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 2005;65:11572-80. (Pubitemid 41821716)
37. Park KS, Korfhagen TR, Bruno MD, Kitzmiller JA, Wan H, Wert SE, et al. SPDEF regulates goblet cell hyperplasia in the airway epithelium. J Clin Invest 2007;117:978-88. (Pubitemid 46556754)
38. Ekerot M, Stavridis MP, Delavaine L, Mitchell MP, Staples C, Owens DM, et al. Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J 2008;412:287-98. (Pubitemid 351758234)
39. Nunes-Xavier CE, Tarrega C, Cejudo-Marin R, Frijhoff J, Sandin A, Ostman A, et al. Differential up-regulation of MAP kinase phosphatases MKP3/DUSP6 and DUSP5 by Ets2 and c-Jun converge in the control of the growth arrest versus proliferation response of MCF-7 breast cancer cells to phorbol ester. J Biol Chem 2010;285:26417-30.
40. Cao X, Littlejohn J, Rodarte C, Zhang L, Martino B, Rascoe P, et al. Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. Am J Pathol 2009;175:2207-16.
41. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16. (Pubitemid 351767118)
42. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
43. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008;27:3021-31. (Pubitemid 351668011)
44. Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, Buck SA, et al. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 2008;22:521-9. (Pubitemid 351386721)
45. Ito Y, Miyoshi E, Takeda T, Sakon M, Ihara S, Tsujimoto M, et al. Ets-2 overexpression contributes to progression of pancreatic adenocarcinoma. Oncol Rep 2002;9:853-7.
46. Foos G, Garcia-Ramirez JJ, Galang CK, Hauser CA. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation. J Biol Chem 1998;273:18871-80. (Pubitemid 28366274)
47. Hever A, Oshima RG, Hauser CA. Ets2 is not required for Ras or Neu/ErbB-2 mediated cellular transformation in vitro. Exp Cell Res 2003;290:132-43. (Pubitemid 37153257)
48. Agathanggelou A, Bieche I, Ahmed-Choudhury J, Nicke B, Dammann R, Baksh S, et al. Identification of novel gene expression targets for the Ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res 2003;63:5344-51. (Pubitemid 37139849)
49. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA. Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 2005;172:729-37. (Pubitemid 41324228)